ImmunoGen axes 75% of staff to fund new clinical trial
June 28, 2019 at 05:36 AM EDT
After its Phase 3 trial failed, ImmunoGen has opted to continue testing its ovarian cancer drug in a subgroup of patients with high rates of a protein called folate receptor alpha.